Orgenesis Inc., a leader in the emerging fields of cellular therapy and re-generative medicine has signed a strategic agreement with MaSTherCell SA of Gosselies, Belgium. The agreement should enable Orgenesis to advance its manufacturing process from lab scale to clinical scale as it prepares for Phase I and Phase II clinical trials of its new therapy to treat Type 1 diabetes.
Orgenesis is a pioneer in the field of cellular trans-differentiation which could transform a Type 1 diabetic patient’s own liver cells into new insulin-producing cells. Cellular trans-differentiation involves a complex biologic process, and requires sophisticated manufacturing technology and capabilities.
Services will commence upon approval of The Directorate General operational for Economy, Employment and Research (DGO6) of Belgium, which will be providing grants to fund the research and manufacturing activities.
Orgenesis believes that converting the diabetic patient’s own tissue into insulin-producing liver cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. www.orgenesis.com
This news item first appeared in our free-to-receive online magazine. We cover diabetes news, diabetes management equipment (diabetes kit) and food news for the diabetic diet. Go to the top of this page to sign up – we just need your email address.